Improvements in factor concentrates

Current Opinion in Hematology

Volumn 17, Issue 5, 2010, Pages 393-397

  Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

clotting factor prophylaxis; concentrates; hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9 FC RECEPTOR FUSION PROTEIN; BLOOD CLOTTING FACTOR CONCENTRATE; FC RECEPTOR; HYBRID PROTEIN; LIPOSOME; MACROGOL; POLYMER; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

BLEEDING; CLINICAL TRIAL; DISEASE MODEL; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; HEMOPHILIA; HUMAN; LIPOSOMAL DELIVERY; MUSCULOSKELETAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

DRUG DESIGN; FACTOR IX; FACTOR XIIIA; HEMOPHILIA A; HEMOPHILIA B; HUMANS; RECOMBINANT PROTEINS;

EID: 77955925339     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833c06c6     Document Type: Review

References (32)

1. Bloom AL Progress in the clinical management of haemophilia. Thromb Haemost 1991; 66:166-177.
2. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370:439-448.
3. Mannucci PM, Tuddenham EG. The hemophilias: from royal genes to gene therapy. N Engl J Med 2001; 344:1773-1779.
4. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361:1801-1809.
5. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232:25-32.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535-544.
7. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia 2008; 14:361-374.
8. van DK, Fischer K, van der Bom JG, et al. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130:107-112.
9. Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16:256-262.
10. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4:1228-1236.
11. Barrow RT, Healey JF, Gailani D, et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95:564-568.
12. Schuettrumpf J, Herzog RW, Schlachterman A, et al. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005; 105:2316-2323.
13. Mei B, Chen Y, Chen J, et al. Expression of human coagulation factor VIII in a human hybrid cell line, HKB11. Mol Biotechnol 2006; 34:165-178.
14. Kaufman RJ, Pipe SW, Tagliavacca L, et al. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 1997; 8 (Suppl 2):S3-S14.
15. Malhotra JD, Miao H, Zhang K, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci USA 2008; 105:18525-18530.
16. Dayan I, Robinson M, Baru M. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 2009; 15:1006-1013.
17. Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv 2010; 7:187-201.
18. Powell JS, Nugent DJ, Harrison JA, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6:277-283.
19. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108:3668-3673.
20. Pan J, Liu T, Kim JY, et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood 2009; 114:2802-2811.
21. MolineuxG. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002; 28 (Suppl A):13-16.
22. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006; 30:351-367.
23. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002; 24:1363-1383.
24. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010 [Epub ahead of print].
25. Lenting PJ, Van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5:1353-1360.
26. Lenting PJ, Van MourikJA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92:3983-3996.
27. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3:1692-1701.
28. Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006; 12 (Suppl 3):42-51.
29. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-725.
30. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115:2057-2064.
31. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactiva-tion-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94:11851-11856.
32. Gale AJ, Radtke KP, Cunningham MA, et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006; 4:1315-1322.